RT Journal Article SR Electronic T1 A Phase II Multicentric Trial of S-1 Combined with 24 h-infusion of Cisplatin in Patients with Advanced Gastric Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 1297 OP 1301 VO 25 IS 2B A1 H. IWASE A1 M. SHIMADA A1 T. TSUZUKI A1 Y. HORIUCHI A1 S. KUMADA A1 J HARUTA A1 T. YAMAGUCHI A1 M SUGIHARA A1 K INA A1 K. KUSUGAMI A1 S. GOTO YR 2005 UL http://ar.iiarjournals.org/content/25/2B/1297.abstract AB Background: The aim of this multicentric trial was to determine the clinical toxicities and antitumor effects of a chemotherapy regimen of S-1 combined with cisplatin in patients with inoperable locally or metastatic advanced gastric cancer. Patients and Methods: Forty-two patients were entered into the study. S-1 (80 mg/m2) was administered orally daily for 14 consecutive days and 24-h infusion of cisplatin (70 mg/m2) was administered on day 8 of every 28-day cycle. Results: The overall response rate was 50% and complete response rate was 5%. The most common adverse event was leucopenia, which occurred with grade 3 in 7 patients (16.6%) and grade 4 in 2 patients (4.8%). Non-hematological adverse events were generally mild. The median survival time was 342 days. The 2-year survival rate was 22.9%. Conclusion: This combination chemotherapy is active, convenient and well tolerated in patients with high-grade advanced gastric cancer. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved